Safety Surveillance During the Introduction of Novel Oral Poliovirus Vaccine Type 2 (nOPV2) in the Central African Republic: Findings from Passive AEFI and Active AESI Surveillance
A retrospective study in the Central African Republic evaluating the safety of the novel oral poliovirus vaccine type 2 (nOPV2) through passive and active surveillance systems found a favorable safety profile with a low reporting rate of adverse events, most of which were mild, thereby supporting the vaccine's continued use while highlighting the need for strengthened pharmacovigilance.